APA (7th ed.) Citation

Charytan, C., Bernardo, M. V., Koch, T. A., Butcher, A., Morris, D., & Bregman, D. B. (2013). Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: A randomized, active-controlled, multi-center study. Nephrology, dialysis, transplantation, 28(4), 953-964. https://doi.org/10.1093/ndt/gfs528

Chicago Style (17th ed.) Citation

Charytan, Chaim, Marializa V. Bernardo, Todd A. Koch, Angelia Butcher, David Morris, and David B. Bregman. "Intravenous Ferric Carboxymaltose Versus Standard Medical Care in the Treatment of Iron Deficiency Anemia in Patients with Chronic Kidney Disease: A Randomized, Active-controlled, Multi-center Study." Nephrology, Dialysis, Transplantation 28, no. 4 (2013): 953-964. https://doi.org/10.1093/ndt/gfs528.

MLA (9th ed.) Citation

Charytan, Chaim, et al. "Intravenous Ferric Carboxymaltose Versus Standard Medical Care in the Treatment of Iron Deficiency Anemia in Patients with Chronic Kidney Disease: A Randomized, Active-controlled, Multi-center Study." Nephrology, Dialysis, Transplantation, vol. 28, no. 4, 2013, pp. 953-964, https://doi.org/10.1093/ndt/gfs528.